Poorly Validated Antibodies Are Wasting Millions of Research Samples, Studies Warn

How would you know whether a protein is expressed in a specific cell type, or whether a treatment changes its abundance in tissue? For most biomedical researchers, the answer follows a familiar routine: order an antibody that is supposed to recognize the protein of interest, run the experiment, obtain a clean signal, and draw a conclusion. The trouble, according to a new Primer published in PLOS Biology by Johan Duchêne of Ludwig-Maximilians-University Munich, is that a convincing signal does not guarantee that the antibody actually detected the intended target. Antibodies can bind other proteins, and because the resulting patterns often look biologically plausible, the error can remain invisible until the reagent is independently challenged.

The scale of the problem is not trivial. In one large-scale test, more than half of the antibodies examined were found to be unfit for purpose in at least one of their potential applications. Examples abound in the literature: a 2022 study showed that murine bone marrow macrophages and human monocytes do not express atypical chemokine receptor 1, contradicting earlier reports built on antibody staining, and a 2024 analysis argued that Bax detection across more than 1,400 publications might be flawed because of unreliable reagents. When antibodies fail silently, the consequences ripple outward: incorrect results, wasted time and money, unnecessary animal and human tissue use, and a measurable contribution to the reproducibility crisis that has troubled biomedical research for over a decade.

Concerns about antibody specificity were raised loudly as early as 2015, when researchers estimated that unreliable antibodies were wasting roughly 800 million dollars worldwide every year and called for standardized reagents. The International Working Group for Antibody Validation subsequently proposed five pillars of antibody validation, stressing that validation must be application-specific, since an antibody that works well in a Western blot may fail completely in immunohistochemistry. Yet despite this growing awareness, insufficiently validated antibodies remain in widespread use. Newer initiatives are trying to change that. One of the most prominent, YCharOS, short for Antibody Characterization through Open Science, systematically tests commercially available antibodies using knockout samples, the gold-standard approach for assessing specificity. A signal in a knockout sample, where the target protein has been genetically removed, indicates that the antibody is binding something other than its intended target. By making such data openly available, YCharOS aims to shift validation from an individual laboratory’s troubleshooting exercise toward a shared community resource.

Two complementary studies published in the same issue of PLOS Biology now tackle the question of why the problem persists and what can realistically be done about it. The first, by Biddle and colleagues, quantifies the damage. Drawing on data from the YCharOS platform, the researchers examined 614 antibodies characterized across multiple research applications and identified 97 that failed under every condition tested. They then traced these failed reagents into the scientific literature, analyzing 785 publications in which the antibodies had been used and identifying thousands of animal and human biological samples that had been studied without any reported evidence of validation.

The extrapolation from those findings is sobering. Biddle and colleagues estimate that millions of animal and human tissue samples may have been consumed in experiments involving antibodies that would fail independent testing. Behind each failed antibody lies a chain of experiments, grants, doctoral theses, and animal lives that produced results of uncertain meaning. The study also probed the human side of the problem, surveying scientists about how they choose antibodies. The answers revealed that selection is often skewed by previous use in the laboratory, by what has already been published, and by supplier reputation, rather than by a systematic evaluation of the reagent’s actual performance. In other words, researchers frequently rely on social and commercial signals that correlate poorly with analytical validity.

Identifying a problem is important; providing solutions matters even more. That is the contribution of the second study, by Blades and colleagues, which recognizes a structural feature of the dilemma: the problem cannot be solved simply by asking individual researchers to validate their antibodies more rigorously, and responsibility is distributed across many actors who each tend to assume that someone else will address it. To break that deadlock, the authors conducted a Delphi consensus process, a structured method for building agreement among experts through iterative rounds of evaluation, involving 32 international experts drawn from five stakeholder groups: academic researchers, scientific publishers, research funders, antibody manufacturers, and institutional research leaders.

From a starting list of 33 proposed actions, the participants identified 15 that were judged both effective and feasible to implement by 2030. Crucially, these actions distribute responsibility across the entire research ecosystem rather than piling it onto bench scientists alone. Researchers need access to appropriate training and validation resources; institutions can embed validation standards in core facilities and hiring practices; funders can require validation plans in grant applications; publishers can demand documentation of antibody performance in manuscripts; and manufacturers can supply knockout-validated data with their products. The study thereby moves beyond the generic exhortation that antibodies should be better validated and toward something closer to a roadmap, in which each stakeholder holds a distinct and defined role in improving reagent reliability.

Whether that roadmap translates into changed practice remains an open question. Consensus among stakeholders is a necessary first step, but implementation will demand sustained commitment and coordination across a research system that is notoriously fragmented and slow to alter its habits. The authors of the Primer argue that the next challenge is to make rigorous validation part of routine biomedical research rather than an occasional heroic effort. That challenge may grow more urgent as new technologies reshape how science is done. Artificial intelligence is increasingly used to search and synthesize the scientific literature, but such systems lack critical judgment and do not exclude findings based on poorly validated reagents, making their outputs potentially unreliable. Erroneous conclusions baked into the literature could then be propagated into new analyses, recommendations, and hypotheses at machine speed. Ensuring that future AI tools are trained to account for reagent quality is, in this view, an essential safeguard.

At the same time, artificial intelligence is not only a risk but also a potential source of alternatives. Computational protein design has advanced rapidly, with systems now able to generate protein binders from a target structure alone and tools such as BindCraft enabling one-shot design of functional binders. These designed molecules could complement or even replace conventional antibodies in some applications. But their success, Duchêne notes, will depend on whether the lessons learned from decades of antibody validation are taken into consideration from the start, and on systematic testing of whether the new binders specifically recognize their intended targets. A new generation of reagents that repeats the old mistakes would simply relocate the problem rather than solve it.

The underlying demand uniting all of this work is straightforward: the scientific community needs evidence that the reagents used to generate biomedical findings actually measure what researchers intend them to measure. Building rigorous validation into routine practice, supported by institutions, funders, publishers, and manufacturers, is the path the new studies chart. After all, as the Primer’s title suggests, better validated reagents enable better science, and the ethical as well as the scientific stakes of getting this right could hardly be higher.

Subject of Research: Antibody validation failures in biomedical research and stakeholder-driven solutions

Article Title: Better antibodies, better science

Article References: Duchêne, J. (2026). Better antibodies, better science. PLOS Biology, 24(10), e3004001. https://doi.org/10.1371/journal.pbio.3004001

Image Credits: AI Generated

DOI: 10.1371/journal.pbio.3004001

Keywords: antibody validation, reproducibility crisis, PLOS Biology, YCharOS, knockout samples, research ethics, Delphi consensus, protein binders, artificial intelligence, biomedical reagents, animal tissue waste, stakeholder roadmap